

PATENT
ATTORNEY DOCKET NO. CELL 16.0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
)
Wang et al.) Art Unit: 1814
)
Serial No.: 08/333,680) Examiner: N/A
)
Filed: November 3, 1994)
)
For: NOVEL ADENOVIRAL)
VECTORS, PACKAGING)
CELL LINES, RECOMBINANT)
ADENOVIRUSES AND METHODS)

Express Mail Label No. TB229112873

Date of Deposit: November 29, 1995

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Linda R. Shaw

(Type or print name of person mailing paper or fee)


(Signature of person mailing paper or fee)

TRANSMITTAL LETTER

Hon. Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

Transmitted herewith for filing in the above-captioned patent are:

1. Information Disclosure Statement
2. Form PTO-1449 with copies of 16 references.

As these documents are being filed prior to the receipt of the First Office Action, there should be no filing fee. However, should we be in error the Commissioner is authorized to charge any fees which may be required to Cell Genesys, Inc.'s Deposit Account 03-1184. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

CELL GENESYS, INC.

By: 

Karen I. Krupen
Reg. No. 34,647

Cell Genesys, Inc.
322 Lakeside Drive
Foster City, CA 94404
Tel: 415-358-9600, extension 131

1801



PATENT
ATTORNEY DOCKET NO. CELL 16.0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Transmittal of:

Wang et al.

Serial No.: 08/333,680

Filed: November 3, 1994

For: NOVEL ADENOVIRAL
VECTORS, PACKAGING
CELL LINES, RECOMBINANT
ADENOVIRUSES AND METHODS

)
)
) Art Unit: 1814
)
) Examiner: N/A
)
)
)
)
)
)
)
)

RECEIVED
DEC 15 1995
GROUP 1800

1844

Express Mail Label No. TB229112873 Date of Deposit: November 29, 1995
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.
Linda R. Shaw (Type or print name of person mailing paper or fee)
[Signature] (Signature of person mailing paper or fee)

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

This Information Disclosure Statement and form PTO-1449 are being submitted for the above-identified patent application.

The Applicants hereby submit patents, publications, or other information of which they are aware, which they believe may be material to the examination of the above referenced application and in respect to which there may be a duty to disclose in accordance with 37 CFR 1.56.

In accordance with 37 CFR 1.97(b), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, or that no other material information as defined by 37 CFR 1.56 exists. The disclosure statement herein does not constitute an admission that any patent, publication or other information cited alone or in combination constitutes prior art for the invention under 35 U.S.C. 102 or 103.

LISTING EXPLANATION OF INFORMATION ITEMS

A list of patents and publications is set forth on the attached Form PTO-1449. The list is divided into U.S. Patents, Foreign Published Applications or Patents, and Other Printed Publications so that document identification data prescribed in 37 CFR 1.98 may be conveniently set forth.

U.S. Patents:

None

Foreign Published Applications or Patents:

AA WO 93/19191
AB WO 94/08026
AC WO 95/02697
AD WO 94/28152
AE WO 94/12649

Other Printed Publications:

The Applicant is aware of the following printed publications (listed on form PTO-1449) which may be material to the examination of the referenced application.

- AF Imler et al., "Second Generation Adenoviral and Retroviral Vectors for Gene Therapy of Inherited and Acquired Diseases", Abstract submitted at 1994 Meeting on Gene Therapy, September 21-25, 1994.
- AG Vincent et al., "Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene", nature genetics, 5:130-134, (1993)
- AH Quantin et al., "Adenovirus as an expression vector in muscle cells *in vivo*", Proc. Natl. Acad. Sci., U.S.A., 89:2581-2584, (1992)
- AI Ragot et al., "Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of *mdx* mice", Letters to Nature, 361:647-650, (1993)
- AJ Li et al., "Assessment of Recombinant Adenoviral Vectors for Hepatic Gene Therapy", Human Gene Therapy, 4:403-409, (1993)
- AK Engelhardt et al., "Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver", Proc. Natl. Acad. Sci., USA, 91:6196-6200, (1994)
- AL Yang et al., "Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy", Proc. Natl. Acad. Sci., USA, 91:4407-4411, (1994)
- AM Brody et al., "Adenovirus-Mediated *in Vivo* Gene Transfer", Annals New York Academy of Sciences, 716:90-103, (1994)
- AN Berkner et al., "Generation of adenovirus by transfection of plasmids", Nucleic Acids Research, 11(17):6003-6021, (1983).
- AO Gwo, et al., "Characterization of Mouse Inhibin α Gene and Its Promoter", Biochemical and Biophysical Res. Communications, 186(1):293-300, (1992)
- AP Bridge et al., "Interaction of Adenoviral E4 and E1b Products in Late Gene Expression", Virology, 174:345-353, (1990)


Copies:

Copies of all cited references are enclosed.

The Commissioner is hereby authorized to charge any fees associated with this communication to Deposit Account No. 03-1184. A duplicate copy of this communication is enclosed.

Respectfully submitted,

CELL GENESYS, INC.

By: 

Karen I. Krupen
Reg. No. 34,647

Cell Genesys, Inc.
322 Lakeside Drive
Foster City, CA 94404
Tel: 415-358-9600, extension 131
Enc: PTO Form 1449